Summary We attempted to induce anti-tumour immunity for rejecting pre-B lymphoma derived from Eu/ret transgenic mice (TGM). We established pre-B-lymphoma cell lines of C57BL/6 x Balb/c background (H-2bI/d) into which H-2k alloantigen and C3H background were introduced (retLl-6 and retL6-6), and we inoculated BCF, mice with these immunising tumour cells. After these tumours were rejected by alloantigen (H-2k/C3H background)-specific effector cells, the mice were challenged with the pre-B-lymphoma cell line derived from the original EJL/ret TGM (retO-2). All non-immunised control mice died within 80 days, whereas half the immunised mice survived for over 300 days. The immunity was also effective against primary pre-B-lymphoma cells from Eli/ret TGM and the ret-driven melanoma cell line (MEL-ret), but not against the pre-B-lymphoma cell line from Ejlmyc TGM. This immunity was at least in part mediated by cell-mediated cytotoxicity that was specific to the ret oncogene product or ret-regulated antigen. Next we immunised Ep/ret TGM by inoculating them with retL6-6 cells once every 2 weeks beginning at the age of 1 month. Interestingly, this immunisation enabled the TGM to survive longer than the non-immunised control group (P <0.05). Moreover, 2 of 11 transgenic mice receiving such immunisation were free from both macroscopic and microscopic tumours at the time when all of the 12 non-immunised control TGM had died from their tumour. This provides a new model for oncogene-linked immunotherapy research.
Different types of tumour antigens have been found on malignant tumours in humans and laboratory animals (Klein, 1966; Old and Stockert, 1977; Schreiber et al., 1988; Urban and Schreiber, 1992) . Many of them are simply recognised by antibodies and helper T cells, and only some of them act in rejecting tumours. The former type of antigens are useful for the diagnosis of tumours and for targeting tumours with toxic reagents, but only the latter are active in the immunological surveillance of tumours and can be best used for therapeutic and prophylactic purposes. Well-known tumour rejection antigens are nuclear antigens of tumour viruses such as SV40 T antigen (Klein, 1966) , adenovirus ElA antigen (Dyson et al., 1992) and papillomavirus type 16 nucleoprotein (Chen et al., 1988) , proteolysed fragments (peptides) of which can associate with class I major histocompatibility complex (MHC) antigens to be recognised by cytotoxic T lymphocytes (CTL). So-called unique antigens of chemically induced tumours and ultraviolet-induced tumours (Schreiber et al., 1988 ) also play a role in tumour rejection. Some of them have been characterised as the 85 kDa (Ulrich et al., 1986) and 96 kDa (Srivastava et al., 1986 ) stressinduced proteins or unique class I MHC antigens (Linsk et al., 1986; Stauss et al., 1986) or P9lA (Lurquin et al., 1989) and P198 (Sibille et al., 1990 ) with mutations of a single nucleotide. Little is known, however, about the potential tumour rejection antigens occurring on spontaneously arising tumours in humans and laboratory animals, although the antigen recognised by autologous CTL on human melanomas has been recently shown to be encoded by the tyrosinase gene (Brichard et al., 1993) , and a human homologue of the murine rejection antigen gp96 has been reported (Maki et al., 1990) .
Recent progress in oncology has revealed the multistep actions of oncogenes in oncogenesis (Cory and Adams, 1988) . The products of these oncogenes may be antigenic because of the occurrence of point mutations, deletion mutations or chromosomal translocation (Hellstrom and Hellstrom, 1989 ; Urban and Schreiber, 1992) . There are many reported examples of tumour-specific antigens closely linked to oncogene proteins, such as mutated ras p21 (Feramisco et al., 1985; Pullano et al., 1989; Jung and Schluesener, 1991; Peace et al., 1991) , the bcl-abl fusion protein (Van Denderen et al., 1989) , mutated p53 (Gannon et al., 1990) adid the deletion mutants of epidermal growth factor receptor (Humphrey et al., 1990) . These tumour antigens are, in most cases, recognised by antibodies and helper T cells for antibody production. Exceptions are mutated p53, which is a nuclear suppressor gene product (Yanuck et al., 1993) , and mutated ras proteins produced by recombinant vaccina viruses (Skipper and Stauss, 1993) (Takahashi et al., 1985) , and the Ret protein is expressed in association with cell membrane (Taniguchi et al., 1992 
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Next, we evaluated the specificity of the anti-tumour immunity induced by retL6-6 (Figure 2 ). Even when challenged by primary lymphoma cells from Ell4ret TGM, immunised mice survived longer (P < 0.05) than nonimmunised mice. Interestingly, the anti-tumour immunity induced by immunisation with Elt/ret B-lymphoma cells was also directed against MEL-ret melanoma cells, while no significant effect was observed on Efl4myc TGM-derived pre-B-lymphoma cells. These data suggested that the induced anti-tumour immunity was specific to the ret oncogene product or its closely related antigen.
A further study was conducted to determine whether cellmediated cytotoxicity was induced by the immunising protocol. After inoculation of retL6-6 cells and retO-2 cells into mice and in vitro secondary sensitisation of spleen cells from these mice with retO-2 cells, the effector activity developed to kill retO-2 cells in addition to retL6-6 cells. (Figure 4a-c ). This contrasted with extensive proliferation of lymphoma cells observed in the lymph nodes ( Figure  4d and e) and bone marrow (Figure 4f ) of all mice in the control group. Transmission of the ret gene into those lymphoma-free mice was confirmed by repeated testing from tail DNA.
Discussion
This study shows that pre-B-lymphoma cells arising in the EfL/ret transgenic mouse carry tumour antigens which induce anti-tumour immunity for both in vivo tumour rejection and in vitro tumour cell killing. This immunity was not as strong as that produced by virally or chemically induced tumours. However, the immunity was effective not only in prolonging the survival of mice transplanted with the tumour, but also in suppressing the primary development of the tumour in the TGM in situ (Figure 3) . The latter finding is particularly notable because it for the first time provides evidence that cellular oncogene-induced tumours may be subject to oncogene product-linked immunological surveillance.
Analysis using four different types of ret-transgenic tumour cells as the target of the immunity, all of which except the transgenic ret were genetically compatible with the host immune system, demonstrated that the immunity was retspecific or ret-linked. Three types of ret transgenic tumour 0.1 +0 RetL6-6 immunised mice were inoculated twice with 2 x 106 retO-2 cells. The spleen cells obtained from these mice I week after the last injection of retO-2 were sensitised in vitro with ret0-2 and assayed for the lytic activity against the target cells. The ret-linked anti-tumour immunity was induced by priming with alloantigen (H-2k/d) bearing ret-transgenic cells (retLl-6 or retL6-6). However, the induced immunity was not restricted by the H-2 of the cells for priming, protecting against the challenge of both H-2bId and H-2b ret-transgenic tumours. This finding corresponded to our previous result that priming for the secondary CTL responses to non-H-2 cellular antigens in vivo (Mizoguchi et al., 1988) and in vitro (Ando et al., 1988) is not restricted by the H-2 of the immunising cells for priming, suggesting effective processing of the tumour antigen by host cells for priming.
Our conclusion that the induced immunity was ret-specific may not be surprising by itself, because the transgenic ret of human origin as a model of homologous ret with extensive mutation is expected to produce ret protein with xenogenic epitopes that must be immunogenic to conventional mice. Actually, we succeeded in demonstrating T-cell proliferation response to recombinant ret protein that was injected with Freund's adjuvant into BCF, mice (Dai et al., 1994) . However, it was rather suprising that the immunity induced with either ret-transgenic tumour cells (the present study) or recombinant ret protein (Dai et al., 1994) was active in tumour rejection (in both studies) and tumour cell killing (in this study only), probably including helper type (in the other study) and cytotoxic (in this study) anti-tumour T-cell immunity.
Human proto-ret has 83% sequence homology to mouse proto-ret (Iwamoto et al., 1993) . The present results suggest that such an oncogene product with extensive molecular modification from the native one still works as antigen for anti-tumour immunity. The ret protein was localised on cell membranes (Taniguchi et al., 1992) , and was not therefore expected to work as a strong tumour rejection antigen. The successful induction of tumour rejection immunity to this antigen supports the view that oncogene products with molecular modifications can induce tumour rejection immunity, no matter what the change in the molecular structure or the cellular location of the oncogene products. However, the level of the immunity induced in the present study was not very strong, even when the molecular variation of the oncogene product (human vs mouse) as antigen was extensive and a potentially powerful method of immunisation was used. This may suggest the limitation of the immunity specific to non-nuclear oncogene products.
Even though all the results suggest that the anti-tumour immunity was induced by the transgenic human ret protein bearing xenogenic epitopes or by another transgenic retlinked antigen, we do not know what peptide sequences of the ret protein or ret-linked antigen are the target epitopes of the tumour-rejecting lymphocytes. Use of transfectants of Elt/myc pre-B lymphoma with different segments of ret cDNA might be effective for further characterisation of the ret or ret-linked immunogenic peptide(s) for the anti-tumour immunity. Studies are therefore in progress to establish a hypoxanthine-guanine-phosphoribosyl transferase (HGPRT)-defective mutant of the EfL/myc pre-B lymphoma for selection of such transfectants and to prepare a number of suitable gene constructs for transfection.
The epitopes that should be recognised by tumour-specific T cells in TGM where the tumour arose might, however, be different from those seen by the T cells in the conventional mice transplanted with the tumour. This is because immunological tolerance would be established against the xenogenic epitopes on human ret protein in the T lymphocytes of the former but not the latter mice. For this reason, the transgenic human ret protein might behave like a self antigen, providing a model in which the immunology of the self ret protein can be studied. Why, then, did tumourrejecting immunity develop in TGM as a result of injecting immunising tumour cells in our study? It might be that tolerance was incomplete. It should be remembered that, in 2 of 11 TGM in.the immunised group, no tumours developed during the whole period examined when all TGM in the unimmunised control group died of tumours. There might exist a variation in the level of tolerance among individual TGM, as was previously reported among different lines of SV40 large T antigen TGM (Faas et al., 1987) . Alternatively, some mutation might appear in the ret oncogene during the development of a tumour, creating a new epitope to which TGM are not tolerant. Germline mutations of the ret protooncogene have been reported in human multiple endocrine neoplasia type IIA (Mulligan et al., 1993) . It could be that immunisation with retL6-6 potentially bearing a type of mutation was fully protective against the tumour in which the same type of mutation occurred, but was only partially suppressive against the tumours bearing different types of mutations. Presently, we do not have any evidence for or against either of these alternative views.
Finally some points should be considered regarding the new method of tumour modification used in this study. We introduced H-2 alloantigen into the transgenic tumour by breeding the TGM with an allogenec strain. This trial was an extension of our previous experiments in which we induced tumour rejection immunity against a chemically induced tumour by using tumour cells transfected with an allogeneic H-2K gene (Isobe et al., 1989) . The effectiveness of introduction of the allogeneic gene in inducing tumour rejection immunity has also been reported in a human system (Plautz et al., 1993) . Our present results further confirm the effectiveness of this method of tumour modification, and justify the trial of immunotherapy by introducing the MHC gene into local tumours (Nabel et al., 1992) . However, it still remains unanswered whether or not these methods are superior to others.
